NCT01959243View on ClinicalTrials.gov

Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants

PHASE3CompletedINTERVENTIONAL
Enrollment

507

Participants

Timeline

Start Date

February 22, 2014

Primary Completion Date

April 23, 2014

Study Completion Date

June 23, 2014

Conditions
Hyperemia
Interventions
DRUG

Brimonidine Tartrate

Ophthalmic solution to be applied as directed.

DRUG

Vehicle

Ophthalmic solution to be applied as directed.

DRUG

Sodium Fluorescein

For use as needed during the study for evaluating corneal damage.

DRUG

Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP

For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.

Trial Locations (4)

19148

Bausch Site 2, Philadelphia

21078

Bausch Site 4, Havre de Grace

85032

Bausch Site 3, Phoenix

01810

Bausch Site 1, Andover

All Listed Sponsors
collaborator

ORA, Inc.

INDUSTRY

lead

Bausch & Lomb Incorporated

INDUSTRY

NCT01959243 - Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants | Biotech Hunter | Biotech Hunter